Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant

Roberto I Vazquez-Padron, L. Moreno-Fierros, L. Neri-Bazán, G. A. De La Riva, Rubén López-Revilla

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Recently we demonstrated that recombinant Cry1Ac protoxin from Bacillus thuringiensis is a potent systemic and mucosal immunogen. In this study we compared the adjuvant effects of Cry1Ac and cholera toxin (CT) for the hepatitis B surface antigen (HBsAg) and bovine serum albumin (BSA). The antibody responses of intestinal secretions and serum were determined by ELISA in Balb/c mice immunized through the intragastric (IG) or intraperitoneal (IP) routes. When HBsAg was administered via IG, the anti- HBsAg intestinal response was not enhanced by either Cry1Ac or CT, whereas via IP Cry1Ac increased the anti-HBsAg intestinal immunoglobulin (Ig)G response and CT increased the intestinal IgA and IgM responses. Serum anti- BSA antibodies increased when BSA was co-administered with CT or Cry1Ac by both routes. Cholera toxin and Cry1Ac co-administered via IP increased the IgG anti-BSA response in fluid of the large intestine and CT also increased the IgA and IgM responses slightly. When co-administered via IP, CT and Cry1Ac did not affect the IgG anti-BSA response of the small intestine significantly. We conclude that Cry1Ac is a mucosal and systemic adjuvant as potent as CT which enhances mostly serum and intestinal IgG antibody responses, especially at the large intestine, and its effects depend on the route and antigen used. These features make Cry1Ac of potential use as carrier and/or adjuvant in mucosal and parenteral vaccines.

Original languageEnglish
Pages (from-to)578-584
Number of pages7
JournalScandinavian Journal of Immunology
Volume49
Issue number6
DOIs
StatePublished - Jul 5 1999
Externally publishedYes

Fingerprint

Cholera Toxin
Bovine Serum Albumin
Hepatitis B Surface Antigens
Hepatitis B Antibodies
Large Intestine
Immunoglobulin A
Antibody Formation
Immunoglobulin M
Immunoglobulin G
Serum
Intestinal Secretions
Bacillus thuringiensis protoxin
Small Intestine
Vaccines
Enzyme-Linked Immunosorbent Assay
Antigens
Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant. / Vazquez-Padron, Roberto I; Moreno-Fierros, L.; Neri-Bazán, L.; De La Riva, G. A.; López-Revilla, Rubén.

In: Scandinavian Journal of Immunology, Vol. 49, No. 6, 05.07.1999, p. 578-584.

Research output: Contribution to journalArticle

Vazquez-Padron, Roberto I ; Moreno-Fierros, L. ; Neri-Bazán, L. ; De La Riva, G. A. ; López-Revilla, Rubén. / Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant. In: Scandinavian Journal of Immunology. 1999 ; Vol. 49, No. 6. pp. 578-584.
@article{b4cfdee7d3ff4188a137a8db41f48643,
title = "Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant",
abstract = "Recently we demonstrated that recombinant Cry1Ac protoxin from Bacillus thuringiensis is a potent systemic and mucosal immunogen. In this study we compared the adjuvant effects of Cry1Ac and cholera toxin (CT) for the hepatitis B surface antigen (HBsAg) and bovine serum albumin (BSA). The antibody responses of intestinal secretions and serum were determined by ELISA in Balb/c mice immunized through the intragastric (IG) or intraperitoneal (IP) routes. When HBsAg was administered via IG, the anti- HBsAg intestinal response was not enhanced by either Cry1Ac or CT, whereas via IP Cry1Ac increased the anti-HBsAg intestinal immunoglobulin (Ig)G response and CT increased the intestinal IgA and IgM responses. Serum anti- BSA antibodies increased when BSA was co-administered with CT or Cry1Ac by both routes. Cholera toxin and Cry1Ac co-administered via IP increased the IgG anti-BSA response in fluid of the large intestine and CT also increased the IgA and IgM responses slightly. When co-administered via IP, CT and Cry1Ac did not affect the IgG anti-BSA response of the small intestine significantly. We conclude that Cry1Ac is a mucosal and systemic adjuvant as potent as CT which enhances mostly serum and intestinal IgG antibody responses, especially at the large intestine, and its effects depend on the route and antigen used. These features make Cry1Ac of potential use as carrier and/or adjuvant in mucosal and parenteral vaccines.",
author = "Vazquez-Padron, {Roberto I} and L. Moreno-Fierros and L. Neri-Baz{\'a}n and {De La Riva}, {G. A.} and Rub{\'e}n L{\'o}pez-Revilla",
year = "1999",
month = "7",
day = "5",
doi = "10.1046/j.1365-3083.1999.00534.x",
language = "English",
volume = "49",
pages = "578--584",
journal = "Scandinavian Journal of Immunology",
issn = "0300-9475",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant

AU - Vazquez-Padron, Roberto I

AU - Moreno-Fierros, L.

AU - Neri-Bazán, L.

AU - De La Riva, G. A.

AU - López-Revilla, Rubén

PY - 1999/7/5

Y1 - 1999/7/5

N2 - Recently we demonstrated that recombinant Cry1Ac protoxin from Bacillus thuringiensis is a potent systemic and mucosal immunogen. In this study we compared the adjuvant effects of Cry1Ac and cholera toxin (CT) for the hepatitis B surface antigen (HBsAg) and bovine serum albumin (BSA). The antibody responses of intestinal secretions and serum were determined by ELISA in Balb/c mice immunized through the intragastric (IG) or intraperitoneal (IP) routes. When HBsAg was administered via IG, the anti- HBsAg intestinal response was not enhanced by either Cry1Ac or CT, whereas via IP Cry1Ac increased the anti-HBsAg intestinal immunoglobulin (Ig)G response and CT increased the intestinal IgA and IgM responses. Serum anti- BSA antibodies increased when BSA was co-administered with CT or Cry1Ac by both routes. Cholera toxin and Cry1Ac co-administered via IP increased the IgG anti-BSA response in fluid of the large intestine and CT also increased the IgA and IgM responses slightly. When co-administered via IP, CT and Cry1Ac did not affect the IgG anti-BSA response of the small intestine significantly. We conclude that Cry1Ac is a mucosal and systemic adjuvant as potent as CT which enhances mostly serum and intestinal IgG antibody responses, especially at the large intestine, and its effects depend on the route and antigen used. These features make Cry1Ac of potential use as carrier and/or adjuvant in mucosal and parenteral vaccines.

AB - Recently we demonstrated that recombinant Cry1Ac protoxin from Bacillus thuringiensis is a potent systemic and mucosal immunogen. In this study we compared the adjuvant effects of Cry1Ac and cholera toxin (CT) for the hepatitis B surface antigen (HBsAg) and bovine serum albumin (BSA). The antibody responses of intestinal secretions and serum were determined by ELISA in Balb/c mice immunized through the intragastric (IG) or intraperitoneal (IP) routes. When HBsAg was administered via IG, the anti- HBsAg intestinal response was not enhanced by either Cry1Ac or CT, whereas via IP Cry1Ac increased the anti-HBsAg intestinal immunoglobulin (Ig)G response and CT increased the intestinal IgA and IgM responses. Serum anti- BSA antibodies increased when BSA was co-administered with CT or Cry1Ac by both routes. Cholera toxin and Cry1Ac co-administered via IP increased the IgG anti-BSA response in fluid of the large intestine and CT also increased the IgA and IgM responses slightly. When co-administered via IP, CT and Cry1Ac did not affect the IgG anti-BSA response of the small intestine significantly. We conclude that Cry1Ac is a mucosal and systemic adjuvant as potent as CT which enhances mostly serum and intestinal IgG antibody responses, especially at the large intestine, and its effects depend on the route and antigen used. These features make Cry1Ac of potential use as carrier and/or adjuvant in mucosal and parenteral vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0032971448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032971448&partnerID=8YFLogxK

U2 - 10.1046/j.1365-3083.1999.00534.x

DO - 10.1046/j.1365-3083.1999.00534.x

M3 - Article

C2 - 10354369

AN - SCOPUS:0032971448

VL - 49

SP - 578

EP - 584

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

SN - 0300-9475

IS - 6

ER -